panitumumab
takeda,amgen
['triplet', 'triplete', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'panitumumab']
triplete study pub at simultaneous with #asco22: ras/braf w, mcrc, upfront
mfolfoxiri+pan vs folfox +pan orr;73% vs 76%, p:0.5 pfs; 12.7 vs 12.3 mos, p:0.2 combination of intense cht with panitumumab doesn't provide add benefit. 
Medical Oncologist